Now, under this non-exclusive agreement, Meiogenix will provide Bayer access to their SpiX technology and the research it has built over the years through different programs in rice, maize and wheat.
Meiogenix is developing complementary breakthrough technologies (such as SpiX) to increase the amount of meiotic recombination – an exchange of genetic material during cell division.
Nicolas and team fused an endonuclease enzyme responsible for initiating the meiotic recombination (Spo11) to a DNA binding domain (originally GAL4). This increased the frequency of gene recombination in ‘cold regions’ of the plant genome (which are typically more conserved).
This therefore ‘unlocks’ potential genetic variation from within the plants genome, helping to accelerate the introduction of new characteristics.
Although financial terms were not disclosed in this case, the availability of funding for Crop sciences research is on the rise, demonstrating the urgency of this economic need.
Just recently in Italy, €21M was dished out by the government as an incentive to research such gene technologies (like the cisgenic approach), which speed up natural processes and can help improve crop yields.
As the CEO and co-founder of Meiogenix, Giacomo Bastianelli, affirmed ‘I personally believe that genetic technologies that mimic natural processes will contribute to producing food for generations to come.’
So Meiogenix appears to have an interesting technology on their hands, and it will be interesting to see who follows in Bayer’s footsteps.